The FDA this week is expected to clear for marketing Genentech's Lucentis for treating wet macular degeneration, a major cause of blindness in people over 65. Some doctors currently prescribe another Genentech drug, Avastin, off label to treat the condition, but Lucentis is being described as a breakthrough by specialists because it is the first drug that has been shown in clinical trials to improve vision.

Full Story:

Related Summaries